Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2020 08:30 ET | Source: ARCA biopharma, Inc.

Clinical Data Evaluating Gencaro for the Treatment of Atrial Fibrillation in Heart Failure Patients Featured in Three Presentations at the 2020 Heart Rhythm Scientific Sessions

New data provide additional evidence of efficacy for Gencaro compared to active control in a pharmacogenetically-defined HF population at risk for AF recurrence ° 26% reduction in total time spent...
May 01, 2019 08:30 ET | Source: ARCA biopharma, Inc.

GENETIC-AF Phase 2B Trial Results Published in the Journal of American College of Cardiology: Heart Failure

WESTMINSTER, Colo., May 01, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
February 20, 2019 07:30 ET | Source: ARCA biopharma, Inc.

ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug

FDA Special Protocol Assessment agreement granted for PRECISION-AF clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation in a heart failure population that has no FDA...
August 09, 2018 16:15 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Second Quarter 2018 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., Aug. 09, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
July 31, 2018 08:30 ET | Source: ARCA biopharma, Inc.

ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA on Gencaro Development for Atrial Fibrillation

Single Phase 3 trial may be sufficient for approval of atrial fibrillation indicationPhase 3 clinical trial Special Protocol Assessment submission anticipated 3Q2018Gencaro is in development as...
February 26, 2018 08:00 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Reports Topline Phase 2B Results for GENETIC-AF Clinical Trial

-------------------------------------------------------------------------------------------------- Gencaro Demonstrates Comparable Efficacy to Active Control and Trend for Potential Gencaro...
January 08, 2018 08:30 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Completion of GENETIC-AF Phase 2B Clinical Trial

-------------------------------------------------------------------------------------------------- GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial...
November 09, 2017 16:05 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Third Quarter 2017 Financial Results and Provides Business Update

WESTMINSTER, Colo., Nov. 09, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...